RxDoctor Payments Data

Osama Kandalaft, MD

Internal Medicine · New Haven, CTNPI 1063868065

Payments from drug & device makers

$5,919in general payments, 2019–2025

Across 294 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$779
  • AstraZeneca$569
  • Novo Nordisk$439
  • Lilly USA, LLC$406
  • Astellas Pharma US Inc$328
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$5,82098%
  • Education$992%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,919 in reported general payments places this provider in the 90th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$64,612
Medicare patients
73
Services billed
766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol143$143,401
JardianceEmpagliflozin96$115,725
OzempicSemaglutide99$107,005
Repatha SureclickEvolocumab39$39,310
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$33,378
GlyxambiEmpagliflozin/Linagliptin21$21,455
JanumetSitagliptin Phos/Metformin Hcl18$20,972
MounjaroTirzepatide18$17,971
GemtesaVibegron21$17,540
RybelsusSemaglutide15$14,711
EntrestoSacubitril/Valsartan14$12,894
EliquisApixaban17$12,110
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$6,862
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,608
VascepaIcosapent Ethyl12$3,979

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$569$145,913154 claims
Boehringer IngelheimJardiance, Glyxambi$145$137,180117 claims
Novo NordiskOzempic, Rybelsus$439$121,716114 claims
GSKTrelegy Ellipta, Anoro Ellipta$779$38,98640 claims
MerckJanumet$152$20,97218 claims
Lilly USA, LLCMounjaro$406$17,97118 claims
Sumitomo Pharma America, Inc.Gemtesa$213$17,54021 claims
PfizerEliquis$108$12,11017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →